Product Description
Cobimetinib is an orally bioavailable small-molecule inhibitor of mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), with potential antineoplastic activity. Cobimetinib specifically binds to and inhibits the catalytic activity of MEK1, resulting in inhibition of extracellular signal-related kinase 2 (ERK2) phosphorylation and activation and decreased tumor cell proliferation. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Cobimetinib)
Mechanisms of Action: MAP2K Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Belgium | Bosnia | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | Ireland | Israel | Italy | Latvia | Lithuania | Luxembourg | Malaysia | Netherlands | New Zealand | Norway | Peru | Poland | Portugal | Romania | Russia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay
Approved Indications: Noma | Melanoma
Known Adverse Events: Lymphopenia | Hyponatremia | Hypophosphatemia | Diarrhea
Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Algeria, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Kazakhstan, Kenya, Korea, Latvia, Mexico, Netherlands, New Zealand, Norway, Panama, Peru, Poland, Portugal, Romania, Russia, Serbia, Singapore, Spain, Switzerland, Taiwan, Thailand, Turkey, United Kingdom, United States
Active Clinical Trial Count: 43
Highest Development Phases
Phase 3: Anaplastic Thyroid Carcinoma|Colorectal Cancer|Erdheim-Chester Disease|Glioma|Laryngeal Cancer|Lymphoproliferative Disorders|Melanoma|Multiple Myeloma|Non-Small-Cell Lung Cancer|Ovarian Cancer|Ovarian Diseases|Papillary Carcinoma|Rectal Diseases|Thyroid Cancer
Phase 2: Abnormalities, Multiple|Adenocarcinoma|Arteriovenous Malformations|Bladder Cancer|Brain Cancer|Breast Cancer|Bronchial Cancer|Bronchogenic Carcinoma|Cervical Cancer|Chronic Myelomonocytic Leukemia|Esophageal Cancer|Esophageal Diseases|Gastrointestinal Cancer|Hairy Cell Leukemia|Hemangioma|Histiocytic Disorders, Malignant|Histiocytic Sarcoma|Histiocytosis, Langerhans-Cell|Histiocytosis, Sinus|Hodgkin Lymphoma|Intestinal Cancer|Intestinal Diseases|Juvenile Myelomonocytic Leukemia,|Langerhans Cell Sarcoma|Lymphoma, B-Cell|Lymphoma, Non-Hodgkin|Oncology Solid Tumor Unspecified|Oncology Unspecified|Pancreatic Cancer|Respiratory Tract Cancer|Sarcoma|Skin Cancer|Small Cell Lung Cancer|Squamous Cell Carcinoma|Thoracic Cancer|Tic Disorders|Vision, Low|Xanthogranuloma, Juvenile
Phase 1: Pancreatic Ductal Carcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| DETERMINE | P3 |
Recruiting |
Lymphoproliferative Disorders |
2029-10-01 |
|
| DETERMINE | P3 |
Recruiting |
Ovarian Diseases|Papillary Carcinoma|Laryngeal Cancer|Non-Small-Cell Lung Cancer|Rectal Diseases|Glioma|Multiple Myeloma|Ovarian Cancer|Thyroid Cancer|Colorectal Cancer|Erdheim-Chester Disease|Anaplastic Thyroid Carcinoma|Melanoma |
2029-10-01 |
|
| BO29554 | P3 |
Unknown Status |
Non-Small-Cell Lung Cancer |
2028-08-03 |
|
| B-FAST | P3 |
Recruiting |
Non-Small-Cell Lung Cancer |
2028-08-03 |